|Articles|October 23, 2018

The Future of JAK Inhibitors Figure 1

Author(s)Denise Baldock, Elizabeth Baynton, Amanda Baskett, and Nicola Bailey

External Link - Future-of-JAKs_Figure 1.pdf

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

FDA’s Oncologic Drugs Advisory Committee Recognizes Favorable Risk Benefit for Truqap

ByNicholas Jacobus

May 1st 2026

Asembia ASX26: The Strain on the Development of Infrastructure for Sustainable C&G Therapy

ByMike Hollan,Will Shrank

April 30th 2026

RNA is not just another modality; it is a programmable approach to drug development. Credit: Stock.Adobe.com/xyz+

BMS vs. Moderna vs. Pfizer: The RNA Platform Race

ByThani Jambulingam, PhD

April 30th 2026

MFN and IRA’s Impact of Innovation and Global Strategy: Q&A with Dr. Stella Vnook

ByMike Hollan,Dr. Stella Vnook

April 30th 2026

Teva Enters $900 Million Agreement to Acquire Emalex

ByNicholas Jacobus

April 29th 2026

The Future of JAK Inhibitors Figure 1

Newsletter

Related Content

FDA’s Oncologic Drugs Advisory Committee Recognizes Favorable Risk Benefit for Truqap

Asembia ASX26: The Strain on the Development of Infrastructure for Sustainable C&G Therapy

BMS vs. Moderna vs. Pfizer: The RNA Platform Race

MFN and IRA’s Impact of Innovation and Global Strategy: Q&A with Dr. Stella Vnook

Teva Enters $900 Million Agreement to Acquire Emalex

Trending on PharmExec

Sanofi Officially Appoints Belén Garijo as Chief Executive Officer Following Shareholder Vote

BMS vs. Moderna vs. Pfizer: The RNA Platform Race

Pharmaceutical Executive Daily: Sanofi Appoints Belén Garijo as CEO

U.S. Prescription Drug Spending Set to Exceed $1 Trillion in 2026: Report

Alternative Supply Chain Strategies Companies Should Prioritize